DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Itolizumab
Itolizumab
Biologic Armamentarium in Psoriasis
Downloaded Here
Psoriasis Review
An Anti-CD6 Monoclonal Antibody (Itolizumab)
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Medical Product Quality Report – COVID-19 Issues
Medical Product Quality Report – COVID-19 Issues
Tailored Treatment Options for Patients with Psoriasis and Psoriatic Arthritis – Literature Review of Established and New Biologic Therapies
Announcements
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
Safety and Efficacy of Itolizumab in the Treatment of Psoriasis: A
Itolizumab As the First Line of Treatment in Moderate to Severe Chronic Plaque Psoriasis: a Case Report
Off-Label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical
INN Working Document 05.179 Update 2011
Stembook 2018.Pdf
A Markov Chain Approach for Ranking Treatments in Network Meta-Analysis Anna Chaimani, Raphaël Porcher, Emilie Sbidian, Dimitris Mavridis
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
Alzumab (Psoriasis) - Forecast and Market Analysis to 2022
Top View
A Case Report of Severe Recalcitrant Psoriasis Treated with Itolizumab: a Novel Anti-Cd6 Monoclonal Antibody
(INN) for Biological and Biotechnological Substances
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
Itolizumab – a Humanized Anti-CD6 Monoclonal Antibody with a Better Side Effects Profile for the Treatment of Psoriasis
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Systemic Pharmacological Treatments for Chronic Plaque Psoriasis : a Network Meta-Analysis
Itolizumab in Addressing Symptoms of Acute Respiratory Distress Syndrome (ARDS) with Weaning Off Oxygen Requirements in a COVID-19 Patient: a Case Study
Implication of Monoclonal Antibody for Covid-19
Equillium, Inc. (Exact Name of Registrant As Specified in Its Charter)
Characterization of the in Vivo Immunomodulatory Properties of CD5 and CD6
Targeted Immunomodulators for the Treatment of Moderate-To-Severe Plaque Psoriasis
Therapeutics and Politics: the Evolving Covid-19 Treatment Landscape
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
ALUZUMAB L PI NEW BBIL Logo A4 SIZE.Cdr
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Therapeutic Focus - IL-17 Antibodies Looking Encouraging in Psoriasis
Application No. AU 2020205207 Al (19) AUSTRALIAN PATENT OFFICE
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
Targeted Immunomodulators for the Treatment of Moderate-To-Severe Plaque Psoriasis
Ongoing Trials for Drugs in the Prevention and Treatment of COVID-19
(12) 按照专利合作条约所公布的国际申请w O 2016/050208
WO 2015/105926 Al 16 July 2015 (16.07.2015) P O PCT
Current Trends in Treatment and Management Of
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Targeted Immunomodulators for the Treatment of Moderate-To-Severe Plaque Psoriasis: Effectiveness and Value
Therapeutic Antibodies for the Treatment of Respiratory Tract Infections—Current Overview and Perspectives
Study Protocol Version 5.0 ITOLI-C19-02-I-00 Date 04-Jun-2020
Small Molecules and Antibodies for the Treatment of Psoriasis: a Patent Review (2010-2015)